Holen Sie sich die Stockscreener-App
4.55
4.01%
-0.19
Handel nachbörslich:
4.55
Schlusskurs vom Vortag:
$4.74
Offen:
$4.59
24-Stunden-Volumen:
8.79M
Relative Volume:
2.10
Marktkapitalisierung:
$1.06B
Einnahmen:
$251.85M
Nettoeinkommen (Verlust:
$-72.58M
KGV:
-14.52
EPS:
-0.3134
Netto-Cashflow:
$-63.80M
1W Leistung:
-7.71%
1M Leistung:
-15.90%
6M Leistung:
-33.28%
1J Leistung:
-36.45%
1-Tages-Spanne:
$4.45
$4.705
1-Wochen-Bereich:
$4.45
$5.00
52-Wochen-Spanne:
$4.32
$9.33
Ardelyx Inc Stock (ARDX) Company Profile
Firmenname
Ardelyx Inc
Sektor
Branche
Telefon
510-745-7047
Adresse
34175 ARDENWOOD BLVD., FREMONT, CA
Vergleichen Sie ARDX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ARDX
Ardelyx Inc
|
4.55 | 1.06B | 251.85M | -72.58M | -63.80M | -0.3134 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-03-07 | Fortgesetzt | Ladenburg Thalmann | Buy |
| 2025-03-04 | Eingeleitet | BTIG Research | Buy |
| 2024-11-11 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-07-02 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-18 | Eingeleitet | Raymond James | Strong Buy |
| 2023-09-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2023-08-25 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | Hochstufung | Wedbush | Neutral → Outperform |
| 2022-11-17 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | Herabstufung | Jefferies | Buy → Hold |
| 2021-07-20 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | Herabstufung | Wedbush | Outperform → Neutral |
| 2021-03-23 | Eingeleitet | Wedbush | Outperform |
| 2021-01-06 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-10-20 | Fortgesetzt | Citigroup | Buy |
| 2020-02-18 | Fortgesetzt | Jefferies | Buy |
| 2020-02-12 | Eingeleitet | Citigroup | Buy |
| 2020-02-10 | Eingeleitet | Cowen | Outperform |
| 2019-04-08 | Eingeleitet | Piper Jaffray | Overweight |
| 2018-08-24 | Eingeleitet | Jefferies | Buy |
| 2018-03-19 | Fortgesetzt | Leerink Partners | Outperform |
| 2017-11-29 | Bestätigt | Citigroup | Buy |
| 2017-11-22 | Bestätigt | Ladenburg Thalmann | Buy |
| 2017-10-17 | Fortgesetzt | Leerink Partners | Outperform |
| 2016-03-31 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2016-03-09 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2016-03-03 | Eingeleitet | Citigroup | Buy |
Alle ansehen
Ardelyx Inc Aktie (ARDX) Neueste Nachrichten
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 15, 2024 in Ardelyx LawsuitARDX - ACCESS Newswire
Ardelyx to Share a Post-Hoc Analysis of the OPTIMIZE Study Supporting XPHOZAH® (tenapanor) at the National Kidney Foundation Spring Clinical Meetings - The Manila Times
First-in-Class Kidney Disease Drug XPHOZAH Reveals Breakthrough Clinical Results - Stock Titan
Commit To Purchase Ardelyx At $4, Earn 20.5% Annualized Using Options - Nasdaq
Institutional owners may take dramatic actions as Ardelyx, Inc.'s (NASDAQ:ARDX) recent 6.4% drop adds to one-year losses - simplywall.st
How to Take Advantage of moves in (ARDX) - news.stocktradersdaily.com
Shareholders that lost money on Ardelyx, Inc.(ARDX) should contact Levi & Korsinsky about pending Class ActionARDX - ACCESS Newswire
Ardelyx Requests to Dismiss Class Action Filed by Investors - TradingView
DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - Marketscreener.com
ARDELYX INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus.com
Trading (ARDX) With Integrated Risk Controls - news.stocktradersdaily.com
Ardelyx honors inaugural Derek Forfang award winners By Investing.com - Investing.com Australia
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth - Investing.com
Ardelyx at Barclays Conference: Pipeline Expansion and Revenue Growth By Investing.com - Investing.com UK
Ardelyx honors inaugural Derek Forfang award winners - Investing.com India
Ardelyx Announces the First Recipients of Derek Forfang Patient Advocate Award - The Manila Times
Five Champions of Kidney Disease Advocacy Receive Groundbreaking Ardelyx Recognition - StockTitan
Insider Buying: David Mott Acquires Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty By Investing.com - Investing.com South Africa
Piper Sandler maintains $8 target on Ardelyx shares amid uncertainty - Investing.com India
8,020 Shares in Ardelyx, Inc. (NASDAQ:ARDX) Bought by SBI Securities Co. Ltd. - Defense World
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities By Investing.com - Investing.com South Africa
Ardelyx at Leerink Global Healthcare Conference: Navigating Challenges and Opportunities - Investing.com India
High Growth Tech Stocks In The US With Promising Potential - Simply Wall St
Ardelyx (NASDAQ:ARDX) Earns “Buy” Rating from LADENBURG THALM/SH SH - Defense World
Scotiabank Initiates Coverage of Ardelyx (ARDX) with Sector Outperform Recommendation - Nasdaq
Ardelyx CEO Michael Raab sells $223,198 in stock - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential - Investing.com
Scotiabank sets $15 target for Ardelyx stock, sees growth potential By Investing.com - Investing.com South Africa
Ardelyx, Inc. to Host Earnings Call - ACCESS Newswire
Cantor Fitzgerald Predicts Ardelyx FY2025 Earnings - Defense World
Ardelyx (NASDAQ:ARDX) Raised to Strong-Buy at Cantor Fitzgerald - Defense World
Rhumbline Advisers Purchases 6,070 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Ardelyx (NASDAQ:ARDX) Coverage Initiated by Analysts at BTIG Research - Defense World
BTIG sets Ardelyx stock Buy rating, $14 price target - Investing.com India
BTIG sets Ardelyx stock Buy rating, $14 price target By Investing.com - Investing.com South Africa
BTIG Initiates Ardelyx at Buy With $14 Price Target -March 04, 2025 at 07:10 am EST - Marketscreener.com
BTIG initiates Ardelyx with a Buy, sees attractive entry point after pullback - TipRanks
Class Action Filed Against Ardelyx, Inc. (ARDX) Seeking Recovery for InvestorsContact Levi & Korsinsky - ACCESS Newswire
Ardelyx, Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky - ACCESS Newswire
Reviewing Q32 Bio (NASDAQ:QTTB) & Ardelyx (NASDAQ:ARDX) - Defense World
Shareholders That Lost Money on Ardelyx, Inc. (ARDX) Should Contact Levi & Korsinsky About Pending Class ActionARDX - ACCESS Newswire
Undercovered Dozen: Ardelyx, Aviva, Nutrien, Heartland Express + - Seeking Alpha
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Ardelyx - ACCESS Newswire
Los Angeles Capital Management LLC Has $2.38 Million Stock Position in Ardelyx, Inc. (NASDAQ:ARDX) - MarketBeat
Ardelyx (NASDAQ:ARDX) Stock Price Up 5.3% on Insider Buying Activity - MarketBeat
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
Shareholders of Ardelyx, Inc. Should Contact Levi & Korsinsky Before October 15, 2024 to Discuss Your RightsARDX - ACCESS Newswire
ARDX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Ardelyx, Inc. Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Levi & Korsinsky Reminds Ardelyx Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 15, 2024ARDX - ACCESS Newswire
Finanzdaten der Ardelyx Inc-Aktie (ARDX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Ardelyx Inc-Aktie (ARDX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| RAAB MICHAEL | President & CEO |
Mar 07 '25 |
Option Exercise |
0.99 |
20,834 |
20,626 |
1,676,806 |
| RAAB MICHAEL | President & CEO |
Mar 07 '25 |
Sale |
5.36 |
41,668 |
223,199 |
1,635,138 |
| MOTT DAVID M | Director |
Feb 24 '25 |
Buy |
5.00 |
77,729 |
388,738 |
2,015,494 |
| Williams Laura A | Chief Medical Officer |
Feb 20 '25 |
Sale |
5.62 |
4,941 |
27,783 |
303,804 |
| Renz Justin A | Chief Financial Officer |
Feb 20 '25 |
Sale |
5.62 |
5,171 |
29,077 |
285,968 |
| RAAB MICHAEL | President & CEO |
Feb 20 '25 |
Sale |
5.62 |
22,964 |
129,124 |
1,085,755 |
| GRAMMER ELIZABETH A | See Remarks |
Feb 20 '25 |
Sale |
5.62 |
4,291 |
24,128 |
181,043 |
3.01%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):